Federal Register / Vol. 87, No. 32 / Wednesday, February 16, 2022 / Notices 8845 

II. Topics for Discussion at the Public 

Workshop 

The purpose of the public workshop 

is to obtain input from industry and 

other interested stakeholders on 

identifying generic drug science and 

research initiatives for FY 2023. FDA is 

particularly interested in receiving 

input about the next 5 years of the 

GDUFA science and research program. 

Specific presentations and 

discussions at this workshop will be 

announced at a later date and may differ 

from the topic above. However, input 

about the topic above will help the 

Agency identify and expand its 

scientific focus for the next fiscal year. 

FDA will consider all comments made 

at this workshop or received through the 

docket (see ADDRESSES) as it develops its 

FY 2023 science and research 

initiatives. Information concerning the 

science and research initiatives for 

generic drugs can be found on the 

Science & Research website at https://

www.fda.gov/drugs/generic-drugs/ 

science-research. 

III. Participating in the Public 

Workshop 

Registration: Registration is free. 

Persons interested in attending this 

public workshop must register online at 

https://fda.zoomgov.com/webinar/ 

register/WN_

kY1uqyD1RLqyRL2XU1KDTA. 

Registration may be performed at any 

time before or during the workshop. 

Requests for Oral Presentations: 

During online registration you may 

indicate if you wish to present your 

public comments. Public comment 

presentation requests must be submitted 

by 11:59 p.m. Eastern Time at the end 

of March 11, 2022. We will do our best 

to accommodate requests to make public 

comments. Individuals and 

organizations with common interests are 

urged to consolidate or coordinate their 

presentations, and request time for a 

joint presentation, or submit requests for 

designated representatives to participate 

in the workshop. Based upon the public 

comment presentation requests received 

by March 11, 2022, at 11:59 p.m. Eastern 

Time, we will determine the amount of 

time allotted to each presenter and the 

approximate time each oral presentation 

is to begin; we will select and notify 

participants by March 28, 2022. All 

public comment presentation requests 

must be received by March 11, 2022, at 

11:59 p.m. Eastern Time. If selected for 

presentation, any presentation materials 

must be emailed to 

GDUFARegulatoryScience@fda.hhs.gov 

no later than April 29, 2022, 11:59 p.m. 

Eastern Time. No commercial or 

promotional material will be permitted 

to be presented or distributed at the 

public workshop. 

Streaming Webcast of the Public 

Workshop: This public workshop will 

be webcast. Please register online (as 

described above) to attend the workshop 

remotely. Registrants will receive a 

hyperlink that provides access to the 

webcast on both days. 

FDA has verified the website 

addresses in this document, as of the 

date this document publishes in the 

Federal Register, but websites are 

subject to change over time. 

Transcripts: Please be advised that as 

soon as a transcript of the public 

workshop is available, it will be 

accessible at https://

www.regulations.gov or https://

www.fda.gov/gdufaregscience. It may be 

viewed at the Dockets Management Staff 

(see ADDRESSES). 

Dated: February 10, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–03368 Filed 2–15–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Docket No. FDA–2018–N–3233] 

Request for Nominations on the 

Technical Electronic Product Radiation 

Safety Standards Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

requesting that any industry 

organizations interested in participating 

in the selection of voting industry 

representatives to serve on the 

Technical Electronic Product Radiation 

Safety Standards Committee in the 

Center for Devices and Radiological 

Health notify FDA in writing. FDA is 

also requesting nominations for voting 

industry representatives to serve on the 

Technical Electronic Product Radiation 

Safety Standards Committee. A nominee 

may either be self-nominated or 

nominated by an organization to serve 

as a voting industry representative. 

Nominations will be accepted for 

current vacancies effective with this 

notice. 

DATES: Any industry organization 

interested in participating in the 

selection of an appropriate voting 

member to represent industry interests 

must send a letter stating that interest to 

FDA by March 18, 2022 (see sections I 

and II of this document for further 

details). Concurrently, nomination 

materials for prospective candidates 

should be sent to FDA by March 18, 

2022. 

ADDRESSES: All statements of interest 

from industry organizations interested 

in participating in the selection process 

of voting industry representative 

nominations should be sent to Margaret 

Ames (see FOR FURTHER INFORMATION

CONTACT). All nominations for voting 

industry representatives should be 

submitted electronically by accessing 

the FDA Advisory Committee 

Membership Nomination Portal: https:// 

www.accessdata.fda.gov/scripts/ 

FACTRSPortal/FACTRS/index.cfm or by 

mail to Advisory Committee Oversight 

and Management Staff, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 5103, Silver Spring, 

MD 20993–0002. Information about 

becoming a member of an FDA advisory 

committee can also be obtained by 

visiting FDA’s website at https://

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

FOR FURTHER INFORMATION CONTACT: 

Margaret Ames, Division of 

Management Services, Center for 

Devices and Radiological Health, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 66, Rm. 5213, 

Silver Spring, MD 20993, 301–796– 

5960, email: Margaret.Ames@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency is requesting nominations for 

voting industry representatives on the 

Technical Electronic Product Radiation 

Safety Standards Committee: 

I. General Description of the Committee 

Duties 

This Committee provides advice and 

consultation to the Commissioner of 

Food and Drugs (the Commissioner) on 

the technical feasibility, reasonableness, 

and practicability of performance 

standards for electronic products to 

control the emission of radiation from 

such products and may recommend 

electronic product radiation safety 

standards to the Commissioner for 

consideration. 

II. Selection Procedure 

Any industry organization interested 

in participating in the selection of an 

appropriate voting member to represent 

industry interests should send a letter 

stating that interest to the FDA contact 

(see FOR FURTHER INFORMATION CONTACT) 

within 30 days of publication of this 

document (see DATES). Within the 


jspears on DSK121TN23PROD with NOTICES1
8846 Federal Register / Vol. 87, No. 32 / Wednesday, February 16, 2022 / Notices 

subsequent 30 days, FDA will send a 

letter to each organization that has 

expressed an interest, attaching a 

complete list of all such organizations, 

and a list of all nominees along with 

their current re ́sume ́s. The letter will 

also state that it is the responsibility of 

the interested organizations to confer 

with one another and to select a 

candidate, within 60 days after the 

receipt of the FDA letter, to serve as the 

voting member to represent industry 

interests for the committee. The 

interested organizations are not bound 

by the list of nominees in selecting a 

candidate. However, if no individual is 

selected within 60 days, the 

Commissioner will select the voting 

member to represent industry interests. 

III. Nomination Procedure 

Individuals may self-nominate and/or 

an organization may nominate one or 

more individuals to serve as a voting 

industry representative. Nominations 

must include a current, complete 

re ́sume ́ or curriculum vitae for each 

nominee including current business 

address and telephone number, email 

address if available, and a signed copy 

of the Acknowledgement and Consent 

form available at the FDA Advisory 

Nomination Portal (see ADDRESSES). 

Nominations must also specify the 

advisory committee for which the 

nominee is recommended. Nominations 

must also acknowledge that the 

nominee is aware of the nomination 

unless self-nominated. FDA will 

forward all nominations to the 

organizations expressing interest in 

participating in the selection process for 

the committee. (Persons who nominate 

themselves as voting industry 

representatives will not participate in 

the selection process.) 

FDA seeks to include the views of 

women and men, members of all racial 

and ethnic groups, and individuals with 

and without disabilities on its advisory 

committees and therefore encourages 

nominations of appropriately qualified 

candidates from these groups. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: February 10, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–03257 Filed 2–15–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2019–N–0721] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Accreditation of 

Third-Party Certification Bodies To 

Conduct Food Safety Audits and Issue 

Certifications 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on information 

collection requirements for the 

accreditation of third-party certification 

bodies to conduct food safety audits and 

issue certifications. 

DATES: Submit either electronic or 

written comments on the collection of 

information by April 18, 2022. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before April 18, 

2022. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of April 18, 2022. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2019–N–0721 for ‘‘Agency Information 

Collection Activities; Proposed 

Collection; Comment Request; 

Accreditation of Third-Party 

Certification Bodies to Conduct Food 

Safety Audits and Issue Certifications.’’ 

Received comments, those filed in a 

timely manner (see ADDRESSES), will be 

placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 


jspears on DSK121TN23PROD with NOTICES1